Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas

BACKGROUND: Evaluation for activating mutations in KRAS, NRAS, and BRAF in colorectal cancer (CRC) and in KRAS in pancreatic ductal adenocarcinoma (PDAC) is essential for clinical care. Plasma cell-free DNA (cfDNA) next-generation sequencing (NGS) allows convenient assessment of a tumor’s molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Caughey, Bennett A., Umemoto, Kumiko, Green, Michelle F., Ikeda, Masafumi, Lowe, Melissa E., Ueno, Makoto, Niedzwiecki, Donna, Taniguchi, Hiroya, Walden, Daniel J., Komatsu, Yoshito, D’Anna, Rachel, Esaki, Taito, Denda, Tadamichi, Datto, Michael B., Bando, Hideaki, Bekaii-Saab, Tanios, Yoshino, Takayuki, Strickler, John H., Nakamura, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643595/
https://www.ncbi.nlm.nih.gov/pubmed/37969845
http://dx.doi.org/10.21037/jgo-23-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643595/
https://www.ncbi.nlm.nih.gov/pubmed/37969845
http://dx.doi.org/10.21037/jgo-23-114

Ejemplares similares